Loading...
A 24-week regimen of sofosbuvir and ribavirin (SOF/RBV) is FDA-approved for the treatment of hepatitis C virus (HCV) genotype 1 infection in patients who are ineligible for or intolerant of interferon. Although this regimen is effective, relapse occurs in 15% to 30% of patients. The next generation of HCV genotype 1 regimens such as sofosbuvir/ledipasvir (SOF/LDV) has recently become FDA-approved (Physician's First Watch Oct 14 2014), but it is unknown whether this regimen will be effective in patients who experience relapse after SOF/RBV therapy.
In an ongoing, industry-supported, open-label, phase IIA study, 14 patients with HCV genotype 1 infection with previous relapse after 24 weeks of treatment with SOF/RBV were treated with SOF (400 m…